Uri Aharon - RedHill Biopharma Insider

RDHL -- Israel Stock  

ILS 377.40  15.40  3.92%

Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles Team Manager at Ernst Young Israel and Accounting Intern at Ziv Haft, BDO . He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion.
Age: 35  Executive Since 2011  MBA    
972 3 541 3131  http://www.redhillbio.com
Aharon is a graduate of the Hebrew University and the Academic College for Management, Rishon Lezion .

Management Efficiency

The company has return on total asset (ROA) of (48.58) % which means that it has lost $48.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (84.52) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives


Jony TalMenora Mivtachim Holdings Ltd
Amir ShakedShapir Engineering and Industry
Ron MelnikSuny Electronic Inc Ltd
Moshe MoragJerusalem Economy Ltd
Shimon IrsaiMenora Mivtachim Holdings Ltd
Tali CassifMigdal Insurance and Financial
Zvika ShenfeldPartner Communications Company
Itzhak MenachemMigdal Insurance and Financial
Michal GurKaganMigdal Insurance and Financial
Asaf AshkenazyMigdal Insurance and Financial
Robert RosenKenon Holdings Ltd
Shimon IrShyMenora Mivtachim Holdings Ltd
Roman RosenthalJerusalem Economy Ltd
Eti HirshmanMenora Mivtachim Holdings Ltd
Leybush UlmanMigdal Insurance and Financial
Rona LererMenora Mivtachim Holdings Ltd
Elisha GoldsteinShapir Engineering and Industry
Moran ErezOPC Energy Ltd
Michal LeshemMigdal Insurance and Financial
Abraham ShamayMigdal Insurance and Financial
Oded BercovitzOPC Energy Ltd

Entity Summary

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensedacquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange. It employs 74 people.RedHill Biopharma Ltd (RDHL) is traded on Tel Aviv Stock Exchange in Israel. It is located in 21 Ha'arba'a Street and employs 74 people.

RedHill Biopharma Leadership Team

Patricia Anderson, Vice President - Regulatory Affairs
Micha Chorin, CFO
Ofer Tsimchi, Director
Patrick Mclean, Product Manager
Aida Bibliowicz, Vice President - Clinical Affairs Europe
Ori Shilo, Co-Founder and Deputy CEO of Fin. and Operations
Shmuel Cabilly, Director
Dror BenAsher, Chairman of the Board, CEO
Kenneth Reed, Director
Elkan Gamzu, Product Manager
Adi Frish, Senior Vice President - Business Development and Licensing
Guy Goldberg, Chief Business Officer
Reza Fathi, Sr. VP of RandD
Tom Lang, Vice President - Regulatory & Clinical Affairs
Clara Fehrmann, Product Manager
Pascal Weerts, Director - Corporate and Legal Affairs
Eric Swenden, Director
Dan Suesskind, Director
Gilead Raday, Senior Vice President - Product and Corporate Development
Rick Scruggs, Director
Terry Plasse, Medical Director
Danielle Abramson, Director - Intellectual Property & Research
Uri Aharon, Chief Accounting Officer
Shani Maurice, Vice President - Business Development & Communications
Patricia Bandeira, Product Manager - Oncology
Ira Kalfus, Medical Director
Nurit Benjamini, External Director

Stock Performance Indicators

Current Sentiment - RDHL

RedHill Biopharma Investor Sentiment
Macroaxis portfolio users are evenly split in their perspective on investing in RedHill Biopharma Ltd. What is your perspective on investing in RedHill Biopharma Ltd? Are you bullish or bearish?
50% Bullish
50% Bearish
Currently Active Assets on Macroaxis
Purchased over 20 shares of
a day ago
Traded for 106.27
Purchased over 200 shares of
a day ago
Traded for 10.56
Purchased over 70 shares of
a day ago
Traded for 39.4
Purchased few shares of
a day ago
Traded for 1184.91
Purchased over 40 shares of
a day ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.